Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchestra BioMed HoldingsOBIO +7.00%42 Days Inventory is 961.78 as of Jun. 2026, which is 230% above its 10-year median of 291.46. GuruFocus rates OBIO with a GF Score™ of 42/100 and a GF Value™ of $31.57 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 639 Biotechnology companies, Orchestra BioMed Holdings ranks worse than 86.85% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Orchestra BioMed Holdings's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.09.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orchestra BioMed Holdings's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 2.99.
Orchestra BioMed Holdings (NAS:OBIO) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Orchestra BioMed Holdings's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orchestra BioMed Holdings's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Orchestra BioMed Holdings Days Inventory Related Terms
Orchestra BioMed Holdings Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBIO vs CYDY, IRD, VNDA: Days Inventory Comparison
For the Biotechnology subindustry, Orchestra BioMed Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings (OBIO) has a Days Inventory of 961.78 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Orchestra BioMed Holdings and its competitors. This is 230% above median its historical median of 291.46. Over the past decade, Orchestra BioMed Holdings' Days Inventory has ranged from 125.64 to 644.91. According to the industry distribution chart, Orchestra BioMed Holdings ranks #555 out of 639 companies in the Biotechnology industry, placing it in the top 86.9%.
Is Orchestra BioMed Holdings' Days Inventory too high?
Orchestra BioMed Holdings' current Days Inventory of 961.78 is 230% above median its 10-year median of 291.46. Over the past 10 years, this metric has ranged from a low of 125.64 to a high of 644.91. The Biotechnology industry median Days Inventory is 184.66. Orchestra BioMed Holdings' value of 961.78 is 420.8% above this industry median. Based on the distribution chart, Orchestra BioMed Holdings ranks #555 out of 639 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Days Inventory compare to CYDY and IRD?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #555 out of 639 companies for Days Inventory. This places Orchestra BioMed Holdings in the lower half of its industry. The industry median Days Inventory is 184.66. Orchestra BioMed Holdings' value of 961.78 is 420.8% above this benchmark. Historically, Orchestra BioMed Holdings' own Days Inventory has ranged from 125.64 to 644.91 over the past decade. While the company's 10-year median is 291.46 vs. the industry median of 184.66, Orchestra BioMed Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.66, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchestra BioMed Holdings's current Days Inventory of 961.78 is 420.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Orchestra BioMed Holdings and its competitors. For the Biotechnology industry, the median Days Inventory is 184.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchestra BioMed Holdings's current Days Inventory is 961.78, which is 230% above median its own 10-year median of 291.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.57, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Days Inventory is 961.78, which is 230% above median its 10-year median of 291.46 and 420.8% above the Biotechnology industry median of 184.66. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Days Inventory is 961.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.57.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Days Inventory: 961.78 (230% above median its 10-year median of 291.46)
GF Value™: $31.57 vs. price of $5.81 (81.6% below fair value)
Industry Position: 420.8% above the Biotechnology median (#555 of 639)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score
Get the complete analysis for OBIO
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
